医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BioChain Responds to Epigenomics’ Unilateral Termination of License Contract

2019年03月13日 AM06:43
このエントリーをはてなブックマークに追加


 

NEWARK, Calif.

BioChain, a US-based company, said today Epigenomics AG of Germany seriously violated the terms of an ongoing licensing contract by publicly announcing on March 6, 2019 the unilateral termination of BioChain’s licensing right of Septin9 marker in China. The termination of the contract by Epigenomics is not legally effective.

BioChain’s CEO, Grace Tian stated that according to the terms of the contract, disputes between the two parties require the parties to go through a mediation and arbitration process. BioChain filed a request with the contractually specified mediation and arbitration center on March 1, 2019 in accordance with the contract, before Epigenomics unilaterally terminated the contract.

BioChain and its affiliates, as the exclusive licensee of Septin9 marker in China, have diligently worked to expand its market position despite challenging market conditions, including the fact that one relevant patent of Epigenomics was invalidated in China and the news was publicly published in May 2018.

Tian said, “Epigenomics’ termination of the Septin9 contract has incurred damages to BioChain’s reputation and investment and BioChain will take further legal actions to protect its interests”.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005925/en/

CONTACT

Company: BioChain Institute Inc. 39600 Eureka Drive, Newark, CA 94560,
Tel 510-783-8588

Business Relations: Xiaoshan Wang, Tel 510-717-2859, E-Mail: br@biochain.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高